Bismuth subsalicylat
 OpenBabel02212023462D

 12 10  0  0  0  0  0  0  0  0999 V2000
   -0.8574    1.4025    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1429    0.9900    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5716    1.4025    0.0000 O   0  5  0  0  0  0  0  0  0  0  0  0
   -0.1429    0.1650    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5716   -0.2475    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2860    0.1650    0.0000 O   0  5  0  0  0  0  0  0  0  0  0  0
    0.5716   -1.0725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1429   -1.4850    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8574   -1.0725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8574   -0.2475    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6432    0.0000    0.0000 Bi  0  1  0  0  0 15  0  0  0  0  0  0
    0.0000   -3.1350    0.0000 O   0  5  0  0  0  0  0  0  0  0  0  0
  1  2  2  0  0  0  0
  2  3  1  0  0  0  0
  2  4  1  0  0  0  0
  4  5  2  0  0  0  0
  4 10  1  0  0  0  0
  5  6  1  0  0  0  0
  5  7  1  0  0  0  0
  7  8  2  0  0  0  0
  8  9  1  0  0  0  0
  9 10  2  0  0  0  0
M  CHG  4   3  -1   6  -1  11   3  12  -1
M  END
>  <CdId>
314

>  <Mol Weight>
362.0926

>  <Formula>
C7H5BiO4

>  <ID>
T0424

>  <Name>
Bismuth subsalicylat

>  <Synonyms>
Bismuth oxysalicylate;Bismuth(III) salicylate basic

>  <CAS>
14882-18-9

>  <Approved status>
FDA

>  <Disease>
Immune system

>  <Indication>
Inflammatory

>  <Pathways>
Immunology/Inflammation; Neuroscience

>  <Target>
COX inhibitor

>  <Receptor>
COX-1; COX-2

$$$$
